Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Biotechnology

Healthcare
$305.19 +4.49%

+$12.13 today

Market cap
$8.53B
Beta
2.75
P/E (TTM)
-25.0
EPS (TTM)
-$11.31
52W Low $37.19High $366.52

Volume 0.43M

Average 0.45M

PRAX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Praxis Precision Medicines, Inc.NASDAQ: PRAX

Operating Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Operating cash flow grows, but more slowly than its trailing trend

Q3 FY2026 operating cash flow of $81.74M (cash outflow) rose 26.3% year over year, behind the +41.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 5.3% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.

Context

  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +26.3% toward the trailing-twelve-month pace of +41.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$81.74M+5.3% QoQ
Last fiscal yearDec 2025
-$249.07M+89.0% YoY
LTMSep 2026
-$322.69M+41.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.3%——
1 year+89.0%——
3-year CAGR+10.4%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(249.07M) USD
Year-over-year change
-89.0%

Operating Cash Flow vs competitors

How PRAX compares with its peers on the latest reported figures

  • PRAX's LTM Sep 2026 operating cash flow of $322.69M is the 4th largest of the 10 companies compared; the peer median is $71.26M.
  • Its year-over-year change of +41.4% is the 2nd highest of 10, against a peer median of +3.4%.
  • Over three fiscal years its annual growth of +10.4% compares with a peer median of +20.3%.
PRAX Competitors Peer median
Operating Cash Flow for PRAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.07B +67.4%+32.1%28.8%
DNLIDenali Therapeutics Inc.LTM Jun 2026$434.04M +24.1%+19.0%12043.3%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$356.1M +41.3%+41.5%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$322.69M +41.4%+10.4%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$194.3M +3.4%—17.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M -3.0%+21.6%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$80.3M +19.0%+199.9%401.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$71.26M -40.9%-7.1%9.2%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$34.08M -4.3%+17.2%—
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$19.91M -89.4%-26.0%2.4%
Peer median (excluding PRAX) $71.26M+3.4%+20.3%22.9%

Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.06M)(214.03M)(123.28M)(182.82M)(303.27M)
Depreciation & Amortization182K419K432K358K140K
Deferred Income Tax2.09M0000
Stock-Based Compensation22.69M28.59M24.86M41.36M33.94M
Change in Working Capital16.13M(1.78M)(13.03M)10.92M22.68M
Accounts Receivables00000
Inventory00000
Accounts Payables7.27M3.89M(8.86M)6.71M12.1M
Other Working Capital8.87M(5.67M)(4.17M)4.21M10.58M
Other Non-Cash Items1.41M1.76M(121K)(1.58M)(2.56M)
Operating Cash Flow(124.55M)(185.04M)(111.14M)(131.76M)(249.07M)
Capital Expenditures(1.05M)(444K)(50K)0(56K)
Acquisitions (Net)139.47M(97.33M)000
Purchases of Investments(164.17M)(83.02M)0(371.52M)(623.81M)
Sales of Investments24.7M180.36M39M123.03M312.72M
Other Investing Activities(139.47M)97.33M000
Investing Cash Flow(140.52M)96.89M38.95M(248.49M)(311.15M)
Debt Repayment(763K)0000
Common Stock Issued105.71M9.56M91.59M512M704.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.64M904K279K2.33M(2.09M)
Financing Cash Flow107.59M10.47M91.87M514.32M702.17M
Effect of Forex Changes00000
Net Change in Cash(157.49M)(77.69M)19.69M134.07M141.96M
Free Cash Flow(125.6M)(185.49M)(111.19M)(131.76M)(249.12M)

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Intrinsic Alpha fair value

Locked

Current Price

$305.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.